

# BMJ Open Cross-sectional study of chronic hepatitis B virus infection in Rwandan high-risk groups: unexpected findings on prevalence and its determinants

Justine Umutesi <sup>1,2</sup>, Carolina Klett-Tammen,<sup>1</sup> Sabin Nsanzimana,<sup>3</sup> G Krause,<sup>1,4</sup> J J Ott<sup>1,5</sup>

**To cite:** Umutesi J, Klett-Tammen C, Nsanzimana S, *et al*. Cross-sectional study of chronic hepatitis B virus infection in Rwandan high-risk groups: unexpected findings on prevalence and its determinants. *BMJ Open* 2021;**11**:e054039. doi:10.1136/bmjopen-2021-054039

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-054039>).

Received 02 June 2021  
Accepted 06 December 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany

<sup>2</sup>IHDPC, Rwanda Biomedical Center, Kigali, Rwanda

<sup>3</sup>Office of the Director General, Rwanda Biomedical Center, Kigali, Rwanda

<sup>4</sup>Epidemiology, DZIF, Braunschweig, Niedersachsen, Germany

<sup>5</sup>MHH, Hannover, Niedersachsen, Germany

## Correspondence to

Dr Justine Umutesi;  
[justine.umutesi@helmholtz-hzi.de](mailto:justine.umutesi@helmholtz-hzi.de)

## ABSTRACT

**Objectives** Using secondary data from 208 079 Rwandans, we determined the prevalence of chronic hepatitis B virus (HBV) infection among high-risk groups and its demographic, geographical and health-related determinants.

**Design** In this cross-sectional study, we obtained and analysed data from a national hepatitis B vaccination and screening campaign conducted in Rwanda in 2017. We performed logistic regression to examine associations between chronic HBV infection and related factors such as risk status and geographical characteristics.

**Setting** Individuals were sampled nationally in all 30 districts across 4 provinces and the city of Kigali and all prisons in Rwanda.

**Participants** The study involves 208 079 individuals at high risk including prisoners and other high-risk groups (oHRG).

**Main outcome** The primary outcome for our study was hepatitis B surface antigens (HBsAg) prevalence.

**Findings** From 208 079 adults participants, 206 517 (99.2%) had valid HBsAg results, 4.3% of 64 944 prisoners and 4.0% of 140 985 oHRG were HBV positive. The prevalence was higher in Northern Province 5.1%, (95% CI 4.8 to 5.4). In multivariate analysis, the odds of infection decreased with increasing age, and hepatitis C antibody positivity reduced the odds for chronic HBV (OR 0.58, 95% CI 0.52 to 0.66 and OR 0.74, 95% CI 0.62 to 0.89 among oHRG and prisoners, respectively). In addition, being female was associated with lower odds of HBV (OR 0.70, 95% CI 0.66 to 0.74 and OR 0.80, 95% CI 0.65 to 0.98 among oHRG and prisoners, respectively).

**Conclusion** We found that individuals below 55 years of age and individuals who belong to high-risk groups (ie, sex workers, injection drug users, men who have sex with men, etc) have a higher probability of chronic HBV infection. Infection with chronic hepatitis C virus was not correlated with chronic HBV infection in our study population. Potential explanations include differential routes of transmission, specific immunological and pathophysiological factors or different effects of health prevention and control programmes.

## INTRODUCTION

WHO released the first global health sector strategy towards ending viral hepatitis by

## Strengths and limitations of this study

- This study used extensive national data from hard-to-reach individuals, with the active participation of local community health workers staff.
- Given the self-selection of study participants, the results of our study are therefore subject to selection bias.
- Underestimation of the prevalence by this study is likely because people chronically infected and debilitated by hepatitis B and/or C may be unable to reach screening sites far from their homes.
- For some populations, including injecting drug users, men who have sex with men, and sex workers, the verification of self-reported status may have escaped the attention of outreach staff, effectively failing to ascertain their true status and thus including some who may not be at high risk.
- Individuals belonging to other high-risk groups could not be disentangled to show a distinct prevalence by category.

2030.<sup>1</sup> In 2019, chronic hepatitis B infection was estimated to affect 296 million people worldwide.<sup>2</sup> Population groups at increased risk of infection include people living with HIV/AIDS,<sup>3</sup> prisoners,<sup>4,5</sup> healthcare providers (HCPs),<sup>6,7</sup> injecting drug users (IDU) and men who have sex with men,<sup>8</sup> female sex workers (FSW)<sup>9</sup> and people of lower socioeconomic status.<sup>10,11</sup>

An estimated 68% of chronic hepatitis B virus (HBV) infections occur in Africa<sup>12</sup> with a prevalence reaching 22%–38% in some countries.<sup>13</sup> Despite widespread infection, limited access to diagnostic tools leaves many infected individuals undiagnosed. Consequently, epidemiological data on chronic HBV from this region are often limited in geographical or temporal resolution while evidence suggest that chronic infection with hepatitis B leads to severe outcomes like liver cancer and death.<sup>14,15</sup>



Rwanda is a landlocked country in east-central Africa, bordered by Burundi to the south, Uganda to the north, Tanzania to the east and the Democratic Republic of Congo to the west. Previous nationwide data from 24 of 30 administrative districts in Rwanda showed a chronic HBV prevalence of 3.9%<sup>16</sup> in the general population, and 2%<sup>17</sup> in a most recent survey that covered all districts of the country. Other smaller studies conducted within specific subpopulations in the country estimated the prevalence to be 2.9% among HCPs from one referral hospital, 4.3% among HIV-positive people,<sup>18</sup> 4.1% among blood donors<sup>19</sup> and 3.7% among pregnant women.<sup>20</sup> However, to our knowledge, there have been no large-scale studies conducted among high-risk groups in Rwanda, such as FSWs, men who have sex with men and people who inject drugs.

Rwanda implemented immunisation against hepatitis B for infants in 2002 in order to prevent HBV transmission.<sup>21</sup> A catch-up vaccination campaign for individuals born prior to 2002 was conducted from June to October 2017 and was coupled with screening for both HBV and hepatitis C virus (HCV) infection. The campaign first targeted people most at risk for infection such as (1) prisoners<sup>22</sup> and (2) other individuals comprehensively defined as other-high-risk groups (oHRG), including people in lower socioeconomic status, individual aged 45 years and above, HCPs,<sup>6,7</sup> IDUs, men who have sex with men<sup>8</sup> and FSWs.<sup>9</sup> Prisoners were screened in their respective prisons, oHRG were invited through the different communication channels and social media (radio, television, WhatsApp messages, online news or newspapers), during religious gatherings, at health facilities or at community events. Samples were collected by nurses and laboratory technicians from National Reference Laboratory and performed by 13 satellite laboratories equipped with hepatitis B and C testing machines.<sup>23,24</sup> The laboratory report form captured test results and demographic and geographical information of patients but did not document the specific risk groups.

Chronic HBV infection was defined as positive hepatitis B surface antigens (HBsAg).<sup>25</sup> Blood samples were screened for HBsAg and hepatitis C antibody (anti-HCV) using Murex ELISA (V.3.0, Italy)<sup>18</sup> and Murex ELISA for anti-HCV (V.4.0, Italy), respectively. The objective of this study was to analyse data collected during the 2017 vaccination and screening campaign to investigate chronic HBV prevalence in different high-risk groups across Rwanda and to estimate the demographic and geographical factors associated with chronic infection.

## MATERIALS AND METHODS

### Patient and public involvement

Patients and the public were not involved in the design and planning of this study. However, the results were communicated to them through the health facilities in their catchment area.

### Study design, population and setting

We conducted a cross-sectional analysis of the data extracted from the national database for HIV and viral hepatitis owned by and archived at the Rwanda Biomedical Centre (RBC), the national health implementation institution under the Rwanda Ministry of Health. Our study focuses on data from the HBV screening campaign conducted from June to October 2017 among people aged 15 years and older, including prisoners and other high-risk populations without HBV vaccination.

### Data processing and storage

The original data contained personal identifying data such as names, addresses, blood sample IDs and patient IDs. In compliance with the regulations on the protection of personal data, an authorised employee of the RBC anonymised the data and generated study records according to the list of variables of interest. Variables retained were age, sex, province of residence, socioeconomic status, health insurance and hepatitis B and C screening results. Socioeconomic status was defined as 'poorer' when the person was in ubudehe (A local development programme that classifies citizens into four bottom-up categories, starting with the first category for the poorest, based on assets in terms of land, housing and what families do for a living) category one, 'poor' for category two, 'rich' and 'richer' for category three and four.<sup>26</sup>

### Statistical analysis

The data were analysed after a cleaning process that was carried out with Excel and consisted of correcting typos, renaming, formatting and deleting unrelated or irrelevant information. Duplicates were removed during the anonymisation process, as the current data was received without the possibility of identifying duplicates. We classified age into six categories, 15–24 years, 25–34 years, 35–44 years, 45–54 years, 55–64 years, 65 years and over, where each group has targeted local health services oriented to them.<sup>23,26</sup> Socioeconomic status was assessed according to the 'ubudehe', a four-tiered classification system. Category 1 (16.0% of the population) consists of families without home ownership and can barely afford basic needs. Category 2 (29.8%) consists of individuals who can afford to own or rent a house but cannot obtain a full-time job. Category 3 (53.7%) consists of individuals with stable job or income such as farmers (beyond subsistence farming) and category 4 (0.5%) consists of senior government officials, individuals with large enterprises or working for international organisations and industries.<sup>27</sup> The place of residence was categorised according to five provinces, North, South, West, East and the city of Kigali (CoK). CoK is the only urban province without land borders with other countries. Given the different ways the study participants were recruited and mobilised, we stratified the analysis by two subpopulation groups, prisoners and oHRG. However, prisoners in the CoK were analysed separately because of differential recruitment due to a shortage of tests, which necessitated selecting only

the most at-risk prisoners, including those suspected of being infected with HBV and their results are presented in online supplemental appendix 1.

Previous studies found differences in prevalence of chronic HBV infection between districts,<sup>16,18</sup> thus our study estimated HBV prevalence for each of the 30 districts in Rwanda. In order to present a readable and more informative epidemiological map, we used the definition of endemicity levels from previous studies. High endemicity (HBsAg prevalence of 8% or more), high intermediate endemicity (HBsAg prevalence of 5%–7%), low intermediate endemicity (HBsAg prevalence of 2%–5%) and low endemicity (HBsAg prevalence less than 2%).<sup>28</sup>

We estimated the prevalence of HBsAg in our study population and further cross-tabulated the covariates with prevalence to assess the prevalence stratified by risk group (prisoners or oHRG) and by sociodemographic characteristics of the population. We used the  $\chi^2$  test to test the relationship between categorical variables and selected variables with  $p < 0.1$  for inclusion in the multivariate model. We then conducted a backwards stepwise multivariate logistic regression by sequentially eliminating covariates from the full model and comparing reduced and full models using the likelihood ratio test.

We used a two-sided alpha of 0.05 to assess statistical significance. All analyses were carried out with Stata V.14.2.


#### Informed consent and data protection

The purpose of primary data collection was not to conduct research, but a routine programmatic activity. Details on the data generating process of the initial screening campaign are available in previously published manuscripts (ie, Umutesi *et al*, BMJ Open, 2019). Briefly, oral informed consent was obtained, including consent to screening, testing and the subsequent follow-up procedures including treatment if necessary or research to inform prevention, control and surveillance strategies.

A data protection concept was developed and approved by Federal Commissioner for Data Protection and Freedom of Information in Germany and a data sharing agreement was signed between the Helmholtz Centre for Infection Research and the RBC. The dataset was deidentified, aggregated and prepared by a third party appointed by the RBC in Rwanda.

## RESULTS

The Rwandan national hepatitis vaccination and screening campaign included 208 349 individuals. After excluding 270 persons under 15 years of age, and another 1562 (0.8%) due to unavailable HBsAg serological results, our analysis included 206 517 participants, of whom 140 985 were oHRG and 65 532 were prisoners (figure 1). Prisoners in the CoK (N=588) were analysed separately, (online supplemental appendix 1), reducing the remaining prison population to 64 944 (table 1).



**Figure 1** Study population flow chart. HBsAg, hepatitis B surface antigens; HCVAb, hepatitis C virus antibodies; oHRG, other high-risk group.

#### Characteristics, prevalence of chronic HBV and associated factors among oHRG

Overall, the median age was 52 with IQR of 42–61. The majority were females (64.2%), rich or richer (50%) from the western province (31%) and almost all had health insurance (98%). Apart from socioeconomic status, all other covariates had less than 5% missing.

The overall prevalence was 4.0%. Prevalence was highest among individuals between 25–34 years and 35–44 years (5.0% and 5.3%, respectively), men (5.1%), individuals with health insurance (4.6%), individuals living in the eastern and Northern provinces (4.6% and 5.1%, respectively) and people who tested negative for the HCV (4.2%). Hepatitis B and C coinfection was 2.4%, 95% CI 2.1 to 2.6. In the multivariate analysis, age categories less than 55 years of age was statistically associated with chronic hepatitis B, as was residence in all other provinces compared with the southern province. Women and those who were anti-HCV positive had a lower odds of having chronic hepatitis B (table 1).

#### Characteristics, prevalence of chronic HBV and associated factors among prisoners

The median age was 48 with IQR of 32–58, the majority were males (94.6%), poorer (98.1%) and had health insurance (98%) and from the southern province (51.7%). Chronic HBV was 4.3% and the highest prevalence was found in the individuals below 45 years. Although few prisoners reported their socio-economic status, we found that poor prisoners were more infected (5.0%). A higher prevalence of chronic HBV was also found among prisoners with health insurance (4.3%) and among those incarcerated in Western provinces (5.2%). Hepatitis B and C coinfection was 2.9% (95% CI 2.4 to 3.4). In multivariate analysis, being younger than 45 years of age was statistically associated with chronic HBV. Being incarcerated in eastern and western provinces compared with the southern province was associated with higher prevalence infection. Similar to oHRG, females and positivity for antibodies to hepatitis C had lower odds of chronic HBV (table 2).

**Table 1** Characteristics, prevalence of chronic HBV and associated factors among oHGRs

Characteristics	Overall n=141 903 Tested n=140 985 (%)	HBsAg prevalence (%) 5707 (4.0)	Crude OR (95% CI)	P value*	Adjusted OR (95% CI)	P value†
<b>Age</b>						
15–24	10 858 (7.7)	384 (3.5)	1	<0.001	1	<0.001
25–34	13 922 (9.9)	700 (5.0)	1.44 (1.27 to 1.64)		1.40 (1.23 to 1.61)	
35–44	11 764 (8.3)	626 (5.3)	1.53 (1.35 to 1.74)		1.54 (1.34 to 1.77)	
45–54	43 254 (30.7)	1 768 (4.1)	1.16 (1.04 to 1.30)		1.18 (1.04 to 1.34)	
55–64	33 529 (23.8)	1 235 (3.7)	1.04 (0.93 to 1.17)		1.06 (0.93 to 1.21)	
65+	27 658 (19.6)	994 (3.6)	1.02 (0.90 to 1.15)		1.06 (0.92 to 1.21)	
Unknown	918 (0.6)					
<b>Sex</b>						
Male	50 417 (35.8)	2 549 (5.1)	1	<0.001	1	<0.001
Female	90 416 (64.2)	3 154 (3.5)	0.68 (0.64 to 0.71)		0.72 (0.68 to 0.77)	
Unknown	1 070 (0.8)					
<b>Socioeconomic status</b>						
Poorer	18 133 (14.3)	648 (3.6)	1	0.003	Not analysed	
Poor	45 486 (35.8)	1 758 (3.9)	1.08 (0.99 to 1.19)			
Rich	63 062 (49.6)	2 601 (4.1)	1.16 (1.06 to 1.27)			
Richer	388 (0.3)	11 (2.8)	0.79 (0.43 to 1.44)			
Unknown	14 834 (10.0)					
<b>Health insurance</b>						
No	470 (0.3)	23 (4.9)	Not analysed		Not analysed	
Yes	137 391 (99.7)	5 562 (4.0)				
Unknown	4 042 (2.8)					
<b>Province</b>						
South	29 626 (21.0)	838 (2.8)	1	<0.001	1	<0.001
Kigali	15 963 (11.3)	614 (3.8)	1.37 (1.24 to 1.53)		1.29 (1.15 to 1.45)	
East	32 873 (23.3)	1 528 (4.6)	1.67 (1.54 to 1.82)		1.58 (1.44 to 1.73)	
West	43 613 (30.9)	1 770 (4.1)	1.45 (1.34 to 1.58)		1.36 (1.24 to 1.49)	
North	18 910 (13.4)	957 (5.1)	1.83 (1.66 to 2.01)		1.84 (1.66 to 2.03)	
Unknown	918 (0.6)					
<b>Anti-HCV</b>						
Negative	127 787 (90.9)	5 393 (4.2)	1	<0.001	1	<0.001
Positive	12 718 (9.10)	299 (2.4)	0.55 (.043 to 0.04)		0.58 (0.51 to 0.66)	
Unknown	1 398 (1.00)					

\* $\chi^2$  p value.

†Likelihood ratio test p value (compare models with and without variable).

HBsAg, hepatitis B surface antigens; HBV, hepatitis B virus; HCV, hepatitis C virus; oHGRs, other high-risk groups.

## Maps

Map displays chronic HBV among oHRG across districts in Rwanda (figure 2). The prevalence ranges from 1.8% in Ruhango to 20.2% in Bugesera district. Most of Rwanda's 30 districts have high intermediate endemicity. Nyarugenge, Gasabo and Kicukiro districts make up the capital CoK, had HBsAg prevalence of 5.4%, 3.3% and 4.2%, respectively. No geographical map was displayed

for prisoners as the location of the prisons may not correspond to the prisoner's district of residence.

## DISCUSSION

The national screening campaign underlying this study is one of the largest conducted among people considered to be at high risk of chronic HBV in sub-Saharan Africa.

**Table 2** Characteristics, prevalence of chronic HBV and associated factors among prisoners

Characteristics	Overall n=66 176	HBsAg prevalence (%)	Crude OR (95% CI)	P value*	Adjusted OR (95% CI)	P value†
Tested n=64 944 (%)		2805 (4.3)				
<b>Age</b>						
15–24	6 014 (9.3)	293 (4.9)	1	<0.001	1	<0.001
25–34	11 963 (18.4)	674 (5.6)	1.16 (1.01 to 1.34)		1.17 (1.02 to 1.35)	
35–44	9 316 (14.3)	477 (5.1)	1.05 (0.91 to 1.22)		1.07 (0.92 to 1.25)	
45–54	13 664 (21.09)	556 (4.1)	0.83 (0.72 to 0.96)		0.84 (0.73 to 0.98)	
55–64	13 159 (20.3)	466 (3.5)	0.72 (0.62 to 0.83)		0.74 (0.63 to 0.86)	
65+	10 828 (16.7)	339 (3.1)	0.63 (0.54 to 0.74)		0.69 (0.58 to 0.81)	
<b>Unknown</b>						
<b>Sex</b>						
Male	61 531 (95.4)	2675 (4.3)	1	0.015	1	<0.001
Female	2 955 (4.6)	102 (3.5)	0.79 (0.64 to 0.96)		0.80 (0.65 to 0.98)	
<b>Unknown</b>						
<b>Socioeconomic status</b>						
Poorer	19 729 (98.1)	731 (3.7)	1	0.77	Not analysed	
Poor	99 (0.5)	5 (5.1)	1.38 (0.56 to 3.41)			
Rich	273 (1.4)	11 (4.0)	1.09 (0.59 to 2.00)			
Richer	1 (0.0)	0	Not analysed			
<b>Unknown</b>						
<b>Health insurance</b>						
No	1 018 (1.7)	41 (4.0)	Not analysed		Not analysed	
Yes	59 917 (98.3)	2588 (4.3)				
<b>Unknown</b>						
<b>Province</b>						
South	33 871 (52.2)	1307 (3.9)	1	<0.001	1	<0.001
East	22 973 (35.4)	1076 (4.7)	1.22 (1.13 to 1.33)		1.10 (1.00 to 1.20)	
West	8 100 (12.5)	422 (5.2)	1.37 (1.22 to 1.53)		1.23 (1.10 to 1.38)	
North	no data					
<b>Anti-HCV</b>						
Negative	60 395 (92.7)	2650 (4.4)	1	<0.001	1	<0.001
Positive	4 743 (7.3)	136 (2.9)	0.64 (0.54 to 0.76)		0.74 (0.62 to 0.89)	
<b>Unknown</b>						

\* $\chi^2$  p value.


†Likelihood ratio test p value (compare models with and without variable).

HBsAg, hepatitis B surface antigens; HBV, hepatitis B virus; HCV, hepatitis C virus.

We provide epidemiological estimates for prevalence of chronic HBV infection for 64 944 prisoners in four of the five provinces and 140 985 other high-risk individuals screened in newly established sites across the whole country.

Among oHRG, the prevalence of chronic HBV was 4.0%, lower than the 4.3% found among people living with HIV in Rwanda in a previous study<sup>18</sup> and the 4.3% found among prisoners in our study. The prevalence among the two groups studied are higher than the

2.0% observed in the general population according to a recent Rwandan Population Impact Assessment (RPHIA) survey.<sup>17</sup> In general, similar to previous studies, young age was associated with chronic HBV infection.<sup>29</sup> In addition to not having received infant immunisation services, this population aged 25–54 also includes the population that was born, survived, or participated in the 1994 Rwandan genocide and the war that had widespread impact on society and health infrastructure resulting in the exposure to blood and harmful bodily fluids and poverty.



**Figure 2** Chronic HBV endemicity in the high-risk population by districts of Rwanda. HBsAg, hepatitis B surface antigens; HBV, hepatitis B virus.

Sexual activity, drug and alcohol use are also higher among younger population, factor that increases the risk of chronic HBV infection.<sup>30</sup> On the other hand, the decreasing prevalence in older age groups is not consistently described in the literature. Most elderly people infected with HBV were too ill or not available to participate in screening. Older individuals did not benefit from the hepatitis B infant vaccination that was introduced in 2002. In addition, delays in ensuring blood and injection safety likely contributed to transmission and the lack of available screening and diagnosis services likely reduced the probability of early detection and treatment initiation.

Females had lower odds of chronic HBV in the multivariate analysis, corroborating the lower risk of females compared with males found in other studies,<sup>5 31 32</sup> and higher risk of hepatocellular carcinoma among males in Rwanda.<sup>33</sup> This is possibly due to risky behaviour related to dating FSWs and concurrent partnerships. HIV infection, the virus that is highly considered a co-infection for the HBV is relatively high among FSWs in Rwanda (35.5%).<sup>34 35</sup> HIV prevalence was estimated at 10% among men who have sex with men in the CoK,<sup>36</sup> compared with 3% in the general population of the entire country.<sup>17</sup> Our study did not show a higher risk of HBV infection among women, despite an estimated range of 8853–23 495 active sex workers.<sup>35</sup> The availability of targeted screening and linkage to treatment for FSWs conducted by non-governmental organisations operating in Rwanda may have reduced testing among sex workers who were already aware of their HBV status. For this reason, we believe that men who have sex with men and people who inject drugs (generally more males<sup>37</sup>), estimated at a minimum of 5000 and 1000 in Rwanda, respectively,<sup>34</sup> may outnumber FSWs in the 2017 campaign, increasing the number of infected men relative to women. Another reason is exposure to hairdressing salons and barbershops, which are

more often used by males in African countries and where poor hygiene and lack of sterilisation can contribute to HBV transmission.<sup>38–40</sup> To address this, since 2015, Rwanda's national viral hepatitis policy included mechanisms for prevention<sup>41</sup> such as requiring a machine to sterilise hair clippers for all hairdressers.

This study found that people with anti-HCV positive were less likely to be infected with chronic HBV, that is, OR=0.63 (95% CI 0.57 to 0.69), which is consistent with another study conducted in Rwanda,<sup>24</sup> and could be explained by reduced participation in screening activities due to potential HCV-related illness. However, it is known that infection with HCV and HBV are often concurrent.<sup>42</sup> Immunological studies show that replication of the two viruses is dominated by HCV rather than HBV in their copresence,<sup>43 44</sup> where HCV reduces the replication of HBV among co-infected individuals.<sup>45</sup> Local possibilities for this difference could also be related to unsafe injections and surgeries, behavioural and cultural factors, including scarification,<sup>46 47</sup> where individuals are at higher risk of exposure to HCV than HBV. We also think that the transmission patterns may be different in Rwanda compared with other high-income countries where, unlike Rwanda where injecting drugs is uncommon, most hepatitis research is currently conducted in addition to a significant proportion of people who engage in both injecting drug use and high-risk sexual practices. However, until contrary evidence in Rwanda is provided, we believe that hepatitis C may conceal hepatitis B infection until they are cured so that HBV can be reactivated. This, therefore, suggests the need for retesting for HBsAg after a negative sustained virological response to HCV. Similarly, our study found that women were less likely to be infected with HBsAg and more likely to be exposed to HCV. Given that HBV and HIV share a common mode of transmission and that women are more exposed to HIV,<sup>17 48</sup> we assume that their HBV is also hidden by HCV until they are cured.

Geographical analysis showed that the highest prevalence was in Bugesera district in Eastern Province, mainly due to potential selection bias, as mentioned by the campaign coordinators. However, another survey conducted in 24 Districts including Bugesera in 2018 also found a high prevalence in this region.<sup>16</sup> We hypothesise this could be related to the environmental characteristics. The region is hot with inadequate water supply which can increase the risk of poor hygiene and increase the risk of HBV transmission. Another characteristic shared by districts with high HBV prevalence is the presence of land border with neighbouring countries with fewer HBV prevention and control measures compared with Rwanda. At the time of campaign, Rwanda was only the second country in Africa, after Egypt, to implement viral hepatitis services,<sup>49</sup> and for this reason, cross-border activities may play an important role in increasing prevalence in these districts.

Our study has limitations. First, the data were obtained from electronic records, which are sometimes prone to

missing data or having unmeasured confounding factors and covariates. Our data set had few missing values, which were distributed similarly for characteristics of variables. Second, selection bias might apply, especially since participation in the campaign was voluntary. In addition, the campaign may have over-selected on healthy people, as participants were required to go to testing sites by themselves, thus inadvertently excluding individuals who were unable to travel. Concerns over privacy or discrimination may have further prevented individuals with suspected chronic HBV infection to present for testing. Further, other HBV markers like hepatitis B core antibody could not be tested for further information on exposures. Important risk behaviours such as blood transfusion history, scarification, HIV status etc. were not collected because of the lack of privacy and ease of dialogue with participants. Finally, the data analysed among the prisoners did not include the prisons in the North Province, nor does the geographical epidemiological profile explain the situation among the prisoners, as they may move from one prison to another or be incarcerated in an area different from their residence. Results for prisoners in the capital CoK, presented in the online supplemental appendix 1, may be subject to significant selection bias and should be interpreted with caution. In addition to displaying districts mapping, in order to inform policy and future planning, we have in online supplemental appendix 2, shown the geographical hotspots of chronic HBV infection by provinces in Rwanda in relation to the general population estimates by RPHIA.

In summary, we found a high prevalence of chronic HBV in other high-risk groups with predominance among young people and male indicating age and gender disparity of chronic HBV in Rwanda. Our results also imply the need for follow-up campaigns and implementation of universal access to inexpensive and high-quality diagnostic tests and vaccines targeting individuals not yet screened. Further research can investigate reasons underlying differential prevalence by district which can direct more targeted control activities.

**Acknowledgements** We thank Mr. Eric Remera from the Rwanda Biomedical Centre for assisting with data depersonalisation in Rwanda and Ms. Carol Yingkai Liu for the proof reading of the advanced version of this manuscript.

**Contributors** JU together with JJO developed and initiated the project including research question and hypothesis generation, analyses planning and data protection concept. JU, considered as a guarantor, drafted the manuscript, managed and analysed the data. CK-T supported preparatory steps of the work and provided expertise for the data analyses including independent second analyses as back up. GK was involved in planning and conducting the research; he contributed to interpretation of results and their implications. SN supported data acquirement in Rwanda and prepared relevant steps in the country; JJO supervised the research and guided all steps of manuscript preparation. All authors contributed to writing and have read and approved the manuscript.

**Funding** The German Academic Exchange Service (DAAD) under Rwandan - German PhD Programme, grant number 57398664, supported this work.

**Disclaimer** The views expressed are those of the researchers/authors and not implicitly those of the RBC, HZI or DAAD.

**Map disclaimer** The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply

the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** Approvals from Rwanda National Council for Science and Technology (No 139/NCST.2019), Rwanda National Ethics Committee (No. 958/RNEC/2019) and ethical commission at Hannover Medical School (MHH) in Hannover-Germany (Nr.8604\_BO\_K\_2019) in Hannover-Germany were received.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. The data are under the jurisdiction of the Rwanda Biomedical Center (RBC) and can be obtained from the corresponding author on duly formulated and justified request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iD

Justine Umutesi <http://orcid.org/0000-0001-9408-7685>

#### REFERENCES

- 1 World Health Organization (WHO). *Global health sector strategy on viral hepatitis 2016-2021*, 2016: 56.
- 2 World Health Organization. *Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021*. WHO Press, 2021.
- 3 World Health Organization. *Global hepatitis programme. guidelines for the prevention, care, and treatment of persons with chronic hepatitis B infection*, 2015: 134.
- 4 Memon AR, Shafique K, Memon A, *et al*. Hepatitis B and C prevalence among the high risk groups of Pakistani population. A cross sectional study. *Arch Public Health* 2012;70:9.
- 5 Moradi G, Goodarzi E, Khazaei Z. Prevalence of hepatitis B and C in prisons worldwide: a meta-analysis during the years 2005-2015. *Biomed Res Ther* 2018;5:2235-51.
- 6 Shao ER, Mboya IB, Gunda DW, *et al*. Seroprevalence of hepatitis B virus infection and associated factors among healthcare workers in northern Tanzania. *BMC Infect Dis* 2018;18:474.
- 7 Kateera F, Walker TD, Mutesa L, *et al*. Hepatitis B and C seroprevalence among health care workers in a tertiary hospital in Rwanda. *Trans R Soc Trop Med Hyg* 2015;109:203-8.
- 8 Khosravani A, Sarkari B, Negahban H, *et al*. Hepatitis B infection among high risk population: a seroepidemiological survey in Southwest of Iran. *BMC Infect Dis* 2012;12:1.
- 9 Forbi JC, Onyemauwa N, Gyar SD, *et al*. High prevalence of hepatitis B virus among female sex workers in Nigeria. *Rev Inst Med Trop Sao Paulo* 2008;50:219-21.
- 10 Ali SA, Suhail N, Ali SA. Role of Cultural and Social Barriers in Increased Burden of Hepatitis B in Pakistan : Literature Review. *J Infect Dis Diagnosis* 2016;1:2-7.
- 11 Guimarães LCdaC, Brunini S, Guimarães RA, *et al*. Epidemiology of hepatitis B virus infection in people living in poverty in the central-west region of Brazil. *BMC Public Health* 2019;19:443.
- 12 World Health Organization. *Global hepatitis report, 2017*, 2017: 62.
- 13 Schweitzer A, Horn J, Mikolajczyk RT, *et al*. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015;386:1546-55.



- 14 Stabinski L, Reynolds SJ, Ocama P, *et al.* High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. *Antivir Ther* 2011;16:405–11.
- 15 Butt ZA, Wilkins MJ, Hamilton E, *et al.* Survival of HIV-positive individuals with hepatitis B and C infection in Michigan. *Epidemiol Infect* 2014;142:2131–9.
- 16 Makuza JD, Rwema JOT, Ntihabose CK, *et al.* Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. *BMC Infect Dis* 2019;19:1–10.
- 17 RBC. *Rwanda population-based HIV impact assessment RPHIA 2018-2019*, 2020: 2–8.
- 18 Umutesi J, Simmons B, Makuza JD, *et al.* Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda. *BMC Infect Dis* 2017;17:315.
- 19 Twagirumugabe T, Swaibu G, Walker TD, *et al.* Hepatitis B virus strains from Rwandan blood donors are genetically similar and form one clade within subgenotype A1. *BMC Infect Dis* 2017;17:32.
- 20 Mutagoma M, Balisanga H, Malamba SS, *et al.* Hepatitis B virus and HIV co-infection among pregnant women in Rwanda. *BMC Infect Dis* 2017;17:618.
- 21 Ministry of Health. *Republic of Rwanda :Ministry of Health -Expanded Program on Immunization Comprehensive Multi-Year Plan*, 2011: 1–35.
- 22 Smith JM, Uvin AZ, Macmadu A, *et al.* Epidemiology and treatment of hepatitis B in prisoners. *Curr Hepatol Rep* 2017;16:178–83.
- 23 NISR. *Rwanda demographic and health survey 2014-15*, 2014.
- 24 Umutesi J, Liu CY, Penkunus MJ, *et al.* Screening a nation for hepatitis C virus elimination: a cross-sectional study on prevalence of hepatitis C and associated risk factors in the Rwandan general population. *BMJ Open* 2019;9:e029743.
- 25 Centers for Disease Control and Prevention (CDC). Interpretation of hepatitis B serologic test results. *Mmwr* 2005;54:2005.
- 26 Governance M of L. *Republic of Rwanda NST-1 social protection sector strategic plan (SP-SSP)*, 2018.
- 27 Ezeanya-esiobu C. *The rise of Homegrown ideas and Grassroots voices. new directions in social policy in Rwanda*. United Nations Research Institute for Social Development, 2017.
- 28 Ott JJ, Stevens GA, Groeger J, *et al.* Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 2012;30:2212–9.
- 29 Ie SI, Sidarta E, *et al.* High prevalence of hepatitis B virus infection in young adults in Ternate, eastern Indonesia. *Am J Trop Med Hyg* 2015;93:1349–55.
- 30 Meheus A. Teenagers' lifestyle and the risk of exposure to hepatitis B virus. *Vaccine* 2000;18 Suppl 1:S26–9.
- 31 Ayano G, Tulu M, Haile K, *et al.* A systematic review and meta-analysis of gender difference in epidemiology of HIV, hepatitis B, and hepatitis C infections in people with severe mental illness. *Ann Gen Psychiatry* 2018;17:1–14.
- 32 Tognon F, Sevalie S, Gassimu J, *et al.* Seroprevalence of hepatitis B and hepatitis C among blood donors in Sierra Leone: a multi-year retrospective study. *Int J Infect Dis* 2020;99:102–7.
- 33 Schönfeld I, Kraywinkel K. Epidemiology of hepatocellular carcinoma in Germany. *Onkologe* 2018;24:653–8.
- 34 Rwanda M of health. *Estimating the size of populations through a household survey (ESPHS) Rwanda*, 2012.
- 35 Rwanda Ministry of Health. *Female sex workers population size estimation, Rwanda 2018 3-Source capture – recapture*, 2020.
- 36 Twahirwa Rwema JO, Lyons CE, Herbst S, *et al.* HIV infection and engagement in HIV care cascade among men who have sex with men and transgender women in Kigali, Rwanda: a cross-sectional study. *J Int AIDS Soc* 2020;23 Suppl 6:e25604.
- 37 IAS. Women who inject drugs: overlooked, yet visible. *Policy Brief Ser* 2019;12.
- 38 Khan F, Shams S, Qureshi ID, *et al.* Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. *Virology* 2011;8:225.
- 39 Adoba P, Boadu SK, Agbodzakey H, *et al.* High prevalence of hepatitis B and poor knowledge on hepatitis B and C viral infections among barbers: a cross-sectional study of the Obuasi municipality, Ghana. *BMC Public Health* 2015;15:1041.
- 40 Ngoupa JB, Njukeng PA, Akwa EN. Seroprevalence and associated risk factors for hepatitis B virus infection among barbers and their clients in two cities in Cameroon. *South African J Infect Dis* 2019.
- 41 Rwanda Biomedical Center. *National policy on viral hepatitis prevention and management in Rwanda*, 2015.
- 42 World Health Organization (WHO). *Global health sector strategy on viral hepatitis 2016-2021*, 2016.
- 43 Ortega-Prieto AM, Dorner M. Immune evasion strategies during chronic hepatitis B and C virus infection. *Vaccines* 2017;5:24.
- 44 Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. *J Clin Transl Hepatol* 2018;6:1–10.
- 45 Shih Y-F, Liu C-J. Hepatitis C virus and hepatitis B virus co-infection. *Viruses* 2020;12:741–11.
- 46 Baha W, Foullous A, Dersi N, *et al.* Prevalence and risk factors of hepatitis B and C virus infections among the general population and blood donors in Morocco. *BMC Public Health* 2013;13:50.
- 47 Makuza JD, Liu CY, Ntihabose CK, *et al.* Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program. *BMC Infect Dis* 2019;19:688.
- 48 Joint United Nations Programme on HIV/AIDS (UNAIDS). *Unaids June 2017 HIV core Epidemiology slides*, 2017: 15.
- 49 Schröder SE, Pedrana A, Scott N, *et al.* Innovative strategies for the elimination of viral hepatitis at a national level: a country case series. *Liver Int* 2019;39:1818–36.